睿知中国医院研究地图
候选清单

即将招募食管鳞状细胞癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06756841,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 20 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Screening period tumor patients ECOG performance status score of 0 or 1.

    入选标准第 3 条

  3. Neutrophil count (ANC) ≥1500 cells/mm3

    入选标准第 5 条

    Platelet count ≥100,000 cells/mm3

    入选标准第 6 条

    Hemoglobin ≥9 g/dL or ≥5.6 mmol/L

    入选标准第 7 条

    Serum total bilirubin ≤ 1.5 x ULN.

    入选标准第 8 条

  4. Any active malignant tumor within 5 years before screening.

    排除标准第 9 条

    Patients with positive HIV test.

    排除标准第 11 条

  5. Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.

    入选标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06756841,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged 20 years or older when signing the informed consent form.
  2. Able to provide written informed consent, and understand and follow the study requirements and assessment schedule.
  3. Screening period tumor patients ECOG performance status score of 0 or 1.
  4. Laboratory test data within 7 days before the planned PEF treatment date during the screening period must meet the following standards.
  5. Neutrophil count (ANC) ≥1500 cells/mm3
  6. Platelet count ≥100,000 cells/mm3
  7. Hemoglobin ≥9 g/dL or ≥5.6 mmol/L
  8. Serum total bilirubin ≤ 1.5 x ULN.
  9. Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.

排除标准:Exclusion Criteria:

  1. Subjects with active respiratory tract infection who need antibiotic or antiviral treatment;
  2. Patients with locally advanced ESCC whose tumors can be surgically removed by the investigator or can be potentially cured by radical chemoradiotherapy according to the judgment of local investigators.
  3. Patients with esophageal lesions that severely invade adjacent organs (esophagus/bronchus or esophagus/aorta) and are assessed as high-risk esophageal leakage/fistula by the investigator.
  4. Evidence of complete esophageal obstruction that is not suitable for treatment, and gastroscopy cannot be performed.
  5. Patients with a history of esophageal stent implantation for esophageal obstruction;
  6. Patients with a history of gastrointestinal bleeding in the past 4 weeks, or gastroscopy indicates a high risk of tumor ulcer bleeding.
  7. Patients with obstruction caused by anastomotic stenosis without esophageal primary lesions after previous esophageal cancer surgery.
  8. Patients with active leptomeningeal disease or brain metastasis.
  9. Any active malignant tumor within 5 years before screening.
  10. Subjects have undergone metal implantation surgery such as esophageal stents and airway stents. Or the patient has an implantable cardioverter-defibrillator, pacemaker or other implantable electronic device.
  11. Patients with positive HIV test.
  12. Subjects are currently participating in other research clinical trials;
  13. Subjects who are considered by the investigator to have other high-risk conditions and are not suitable for gastroscopy and surgery;
  14. Subjects who have adverse events that have not yet returned to baseline or stable levels due to previous anti-tumor treatment, except for adverse events that do not pose safety risks (such as hair loss and abnormal values of specific laboratory tests)

引自 ClinicalTrials.gov, NCT06756841, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06756841,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06756841